BCI is pleased to take part in the continuing education day organized by our colleagues in gastroenterology, and to contribute as a speaker on the topic: Localized rectal cancer – Who should not undergo surgery in 2025?

Being able to exchange views with our colleagues European surgeons on the management of rectal cancer patients after an incomplete response or following local excision is always an enriching experience.

These exchanges are essential to improve patient care.

We are delighted to officially welcome Dr. Barbara NOIRET — a skilled and compassionate surgeon — who has decided to continue the journey with us and expand the BCI team.

From March 16, 2026, registration will open for the 2nd edition of the Joint Congress of Visceral and Digestive Surgery (3CVD), which will take place from September 15 to 18, 2026, at CNIT Forest in Paris.

More informations HERE

📢This clinical immersion is designed to provide colorectal surgeons with an in-depth educational experience closely aligned with real operative practice. Through live robotic-assisted procedures, participants will be able to analyze surgical strategies, key steps of dissection, and intraoperative decision-making. 

It is an honor to have been appointed President of the Program Committee of the ESCP Congress of the Future for the next 3 years and thus to participate in writing the program of the next congress which will take place in Paris from September 10 to 12, 2025.

Découvrir le congrès de l'ESCP

Invited as a speaker at the 3rd Colorectal Congress organized in Milan to discuss the advantages and disadvantages of mechanical anastomoses performed transanal approach (TTSS technique) during rectal surgery performed by laparoscopy approach in men and women with rectal cancer.

We are very pleased to announce the election of Professor Quentin DENOST as President of the GRECCAR Group (Rectal Cancer Research Group) for the next 4 years.

We are pleased to have been accepted the abstract "Organ preservation in rectal cancer management : A prospective GRECCAR SNAPSHOT"  for presentation at the 2025 ASCRS Annual Scientific Meeting.

The results of the GRECCAR 4 and PRODIGE 23 randomized trials on the total neaoadjuvant of adjuvant chemotherapy after rectal cancer and the results of the GRECCAR 12 randomized trial on the rôle of neoadjuvant chemotherapy in organ preservation were also selected for presentation at the meeting.

The BCI will attend the JFHOD to present "The Oncological Impact of Adjuvant Chemotherapy After Rectal Resection for Cancer in the TNT Era: Results of Two Randomized Controlled Trials: GRECCAR 4 and PRODIGE 23."

The results presented in this trial are from two randomized controlled trials, GRECCAR 4 and PRODIGE 23, in which the BCI participated.

Discover the program